$谷歌-C(GOOG.US$ $微软(MSFT.US$
Some companies buy back shares to raise capital for reinvestment. This is all good and well until the money isn't injected back into the company. In July 2017, the Institute for New Economic Thinking published a paper titled "US Pharma’s Financialized Business Model" on pharmaceutical companies and their share buyback and dividend strategy.
The study found that share buybacks weren't being used in ways to grow the company, and in many cases, total share buybacks outnumbered funds spent on research and development (R&D). The report stated:
In the name of 'maximizing shareholder value' (MSV), pharmaceutical companies allocate the profits generated from high drug prices to massive repurchases, or buybacks, of their corporate stock for the sole purpose of giving manipulative boosts to their stock prices. Incentivizing these buybacks is stock-based compensation that rewards senior executives for stock-price 'performance.'
And, as mentioned above, any boost to share price from the buyback seems to be short-lived. Along with Apple, Exxon Mobil, and IBM have made significant share repurchases. A CNBC article in May 2017 said since the turn of the century, total outstanding shares of Exxon Mobil have fallen 40%, and IBM's has decreased by a whopping 60% from its peak in 1995. The article notes that not only does this fit "financial engineering," but it also affects overall stock indexes that are valued on the weightings in these companies.
Some companies buy back shares to raise capital for reinvestment. This is all good and well until the money isn't injected back into the company. In July 2017, the Institute for New Economic Thinking published a paper titled "US Pharma’s Financialized Business Model" on pharmaceutical companies and their share buyback and dividend strategy.
The study found that share buybacks weren't being used in ways to grow the company, and in many cases, total share buybacks outnumbered funds spent on research and development (R&D). The report stated:
In the name of 'maximizing shareholder value' (MSV), pharmaceutical companies allocate the profits generated from high drug prices to massive repurchases, or buybacks, of their corporate stock for the sole purpose of giving manipulative boosts to their stock prices. Incentivizing these buybacks is stock-based compensation that rewards senior executives for stock-price 'performance.'
And, as mentioned above, any boost to share price from the buyback seems to be short-lived. Along with Apple, Exxon Mobil, and IBM have made significant share repurchases. A CNBC article in May 2017 said since the turn of the century, total outstanding shares of Exxon Mobil have fallen 40%, and IBM's has decreased by a whopping 60% from its peak in 1995. The article notes that not only does this fit "financial engineering," but it also affects overall stock indexes that are valued on the weightings in these companies.
$Applovin(APP.US$ APP 3 Months Cup with Handle
Not seeing a whole lot to share today but $APP is one worth sharing.
3 months cup with handle
volume pattern looks strong. Would love to see couple of quite days right around the top of of the handle or even one more shake out before the breakout
Not seeing a whole lot to share today but $APP is one worth sharing.
3 months cup with handle
volume pattern looks strong. Would love to see couple of quite days right around the top of of the handle or even one more shake out before the breakout
4
$富途控股(FUTU.US$据估计,今天市场前的93和当天的93是横盘整理。在期权日,它从未大幅上涨。这是比钢铁更硬的定律。
已翻译
1
$阿里巴巴-SW(09988.HK$ 我估计,在今天的市场结束时,SW稳定在148,美国股市的BABA将在清晨大幅上涨。
已翻译
$腾讯控股(00700.HK$ 忍不住再说一遍,腾讯真的在给钱,其他股票很难说,腾讯以这个价格买入,95% 的概率能让你赚钱,收入还可以,当然,如果你期望翻一番,你还是买不到。
已翻译
$潘世奇汽车(PAG.US$ Long PAG CMP 100.54 美元。交易价格高于50均线。上升趋势延续。从杯子和手柄的图案中脱颖而出。可能的目标是112.35美元
已翻译
1
$标普500指数(.SPX.US$ $恒生指数(800000.HK$ 昨天上午美国股市普遍上涨,在周一和周二的沉默之后,香港股市正在寻求情绪爆发。我之前说过,周一和周二的下跌是恶意卖空,这很容易做到,但是在这次下跌之后,情况会平稳得多。但是我的看法没有改变。今天只是稳定和稳定的趋势。具体情况仍取决于明天。明天是关键。
已翻译